Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial

Tingmin Yu, Li He, Xiaosu Yang, Jiying Zhou, Guogang Luo, Hebo Wang, Hongru Zhao, Quan Hu, Fei Ji, Shengyuan Yu, Tingmin Yu, Li He, Xiaosu Yang, Jiying Zhou, Guogang Luo, Hebo Wang, Hongru Zhao, Quan Hu, Fei Ji, Shengyuan Yu

Abstract

Introduction: Over the last two decades, there has been no novel acute treatment for migraine to address the large unmet medical need in Chinese patients. Lasmiditan, a novel selective serotonin 1F receptor agonist (ditan), is anticipated to bring clinical benefit in Chinese patients with migraine. The CENTURION study is a multi-country, placebo-controlled phase 3 study designed to assess the first attack efficacy and the consistency of response of lasmiditan in acute treatment of migraine. This subpopulation analysis pooled Chinese patients' data from the primary cohort and additional extended enrollment cohort which was not published previously. This is the first analysis focusing on lasmiditan's efficacy and safety in Chinese patients with migraine and aims to provide relevant evidence for Chinese physicians.

Methods: Patients were randomized 1:1:1 to one of the three treatment groups for four attacks: (a) lasmiditan 100 mg; (b) lasmiditan 200 mg; or (c) control group. Primary endpoints were pain freedom at 2 h (first attack) and pain freedom at 2 h in at least two out of three attacks. Secondary endpoints included pain relief, sustained pain freedom, and disability freedom.

Results: In total, 281 Chinese patients (lasmiditan 100 mg, 95; lasmiditan 200 mg, 92; control, 94) were treated for at least one migraine attack. Both doses of lasmiditan showed improvement versus placebo for pain freedom at 2 h after first attack, with lasmiditan 200 mg showing nominal significance. An early onset of effect was observed with lasmiditan versus placebo. Both doses of lasmiditan showed better results for all key secondary endpoints versus placebo. The most commonly reported treatment-emergent adverse event across all groups was dizziness.

Conclusion: In the Chinese population, lasmiditan was better than placebo for both primary endpoints and key secondary endpoints with an acceptable safety profile. No new safety signals were detected in the Chinese population. These findings are generally consistent with those observed in the CENTURION study published data and the established product profile.

Trial registration number: NCT03670810.

Keywords: 5-HT1F receptor agonist; Chinese population; Consistency; Efficacy; Lasmiditan; Migraine; Phase 3.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Patient disposition of the Chinese population cohort. N number of participants in population, W/D withdrawal
Fig. 2
Fig. 2
Primary, key secondary, and other endpoints (Chinese ITT population) for a lasmiditan 100 mg versus placebo, b lasmiditan 200 mg versus placebo. CI confidence interval, h hour, ITT intent to treat, MBS most bothersome symptom, OR odds ratio, PGIC Patient Global Impression of Change
Fig. 3
Fig. 3
Time-course up to 6 h a pain freedom b pain relief, first attack

References

    1. Headache Classification Committee of the International Headache Society (IHS). ICHD-3. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
    1. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava, Lifting the Burden: The Global Campaign Against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.
    1. Yu S, Liu R, Zhao G, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–591. doi: 10.1111/j.1526-4610.2011.02061.x.
    1. Yao C, Wang Y, Wang L, et al. Burden of headache disorders in China, 1990–2017: findings from the Global Burden of Disease Study 2017. J Headache Pain. 2019;20(1):102. doi: 10.1186/s10194-019-1048-2.
    1. Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. doi: 10.1186/s10194-018-0899-2.
    1. Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–1876. doi: 10.1056/NEJMra1915327.
    1. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2019;16(9):968–981. doi: 10.1111/j.1468-1331.2009.02748.x.
    1. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20. doi: 10.1111/head.12499.
    1. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–658. doi: 10.1046/j.1468-2982.2002.00404.x.
    1. Zhao H, Zhang L, Ford J, et al. PND64 treatment patterns and real-world outcomes among patients with episodic migraine in China. ISPOR. 2012;24(Supplement 1):S171.
    1. Diener HC. The risks or lack thereof of migraine treatments in vascular disease. Headache. 2020;60(3):649–653. doi: 10.1111/head.13749.
    1. Lamb YN. Lasmiditan: first approval. Drugs. 2019;79(18):1989–1996. doi: 10.1007/s40265-019-01225-7.
    1. Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action - review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71. doi: 10.1186/s10194-020-01132-3.
    1. Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91:e2222–e2232. doi: 10.1212/WNL.0000000000006641.
    1. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–1904. doi: 10.1093/brain/awz134.
    1. Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia. 2021;41(3):294–304. doi: 10.1177/0333102421989232.
    1. Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88–97. doi: 10.1016/j.pharmthera.2018.01.005.
    1. Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018;15(2):291–303. doi: 10.1007/s13311-018-0615-6.
    1. Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia. 2019;39(6):687–710. doi: 10.1177/0333102419828967.
    1. Doty EG, Krege JH, Pohl G, Case M, Dowsett SA, Tepper SJ. Pain freedom at 2 to 8 hours with lasmiditan: a comparison with rimegepant and ubrogepant. Headache. 2020;60(8):1793–1796. doi: 10.1111/head.13899.
    1. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365–391. doi: 10.1146/annurev-physiol-030212-183717.
    1. US Food and Drug Administration. Migraine: developing drugs for acute treatment guidance for industry. . Accessed 28 July 2021.
    1. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. doi: 10.1136/bmj.j2099.
    1. Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8(3):e020498. doi: 10.1136/bmjopen-2017-020498.
    1. Humphrey P, Feniuk W, Perren MJ, et al. Serotonin and migraine. Ann N Y Acad Sci. 1990;600:587–598. doi: 10.1111/j.1749-6632.1990.tb16912.x.
    1. Mitsikostas D, Tfelt-Hansen P. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future. Cent Nerv Syst Agents Med Chem. 2012;12(4):241–249. doi: 10.2174/187152412803760627.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner